title: Using ibutilide to convert atrial fibrillation and flutter.
abstract: Ibutilide fumarate injection is the first antiarrhythmic drug approved by the Food and Drug Administration for acute conversion of atrial fibrillation and flutter of recent onset (up to 90 days). This drug will find its greatest use in critical care units and emergency departments. Critical care nurses monitor the patients, recognize and assist in treating adverse events, and evaluate patient outcomes. Advanced practice nurses will find this information useful for teaching patients, colleagues, and new critical care nurses.
authors.affiliation: dsarg4525@aol.com
authors.forename: D A
authors.initials: DA
authors.lastname: Sargent
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology; D001282:Atrial Flutter / Q000175:diagnosis / Q000188:drug therapy* / Q000451:nursing / Q000503:physiopathology; D003422:Critical Care / Q000379:methods*; D016903:Drug Monitoring; D004562:Electrocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D009730:Nursing Assessment; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; C067192:ibutilide